MIRA Pharmaceuticals is a preclinical-stage pharmaceutical company focused on the development and commercialization of new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive decline typically associated with early-stage dementia. The company is focusing on bringing Ketamir, a drug with the potential to be a game-changer for millions of patients, to market and has taken important steps in that direction.